Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Sees Large Growth in Short Interest

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) saw a significant growth in short interest in the month of October. As of October 30th, there was short interest totaling 2,886 shares, a growth of 5,345.3% from the October 15th total of 53 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 1,238 shares, the days-to-cover ratio is presently 2.3 days.

Orion OYJ Stock Down 1.9%

Shares of ORINY stock traded down $1.13 on Tuesday, hitting $56.92. 290 shares of the stock were exchanged, compared to its average volume of 1,176. The company has a current ratio of 2.64, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $16.07 billion, a P/E ratio of 21.00 and a beta of 0.05. Orion OYJ has a fifty-two week low of $33.62 and a fifty-two week high of $58.15. The business has a 50-day moving average of $49.48 and a 200 day moving average of $42.26.

Orion OYJ (OTCMKTS:ORINY) last announced its earnings results on Wednesday, October 28th. The company reported $0.68 earnings per share (EPS) for the quarter. The business had revenue of $623.96 million for the quarter. Orion OYJ had a return on equity of 54.09% and a net margin of 30.25%.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group upgraded shares of Orion OYJ from a “hold” rating to a “strong-buy” rating in a report on Monday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy”.

About Orion OYJ

Orion Oyj is a Finnish pharmaceutical company that develops, manufactures and markets medicines for human and veterinary use. Its portfolio includes prescription and over-the-counter medicines, as well as active pharmaceutical ingredients supplied to other pharmaceutical companies. Founded in 1917 and headquartered in Espoo, Finland, Orion has a long history in the pharmaceutical industry. The company focuses on areas including oncology, neurology and respiratory diseases, and develops some products in collaboration with international pharmaceutical partners.